- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (333-239661; 333-267000; 333-268854; 333-269421; 333-269711; 333-271729; 333-275733; 333-276367), Form S-3 (333-255751), and Form S-8 (333-265779; 333-270685; 333-276405) of the report dated March 26, 2024 included in this Annual Report on Form 10-K of Panbela Therapeutics, Inc. (the “Company”), relating to the consolidated financial statements of the Company and its subsidiaries as of and for the year ended December 31, 2023 (collectively referred to as, “Audit Report on the 2023 Form 10-K”) and inclusion therein of the Audit Report on the 2023 Form 10-K filed March 26, 2024 with the Securities Exchange Commission.
/s/ Cherry Bekaert LLP
Tampa, Florida
March 26, 2024